Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development. * High-throughput ADME screening * Customised ADME assays * In silico ADME predictive modeling * In vitro toxicology
Looking for a particular Cyprotex employee's phone or email?
Cyprotex Questions
The Cyprotex annual revenue was $31.7 million in 2026.
Paul Walker is the VP, Head of Toxicology and Innovation Efficiency of Cyprotex.
174 people are employed at Cyprotex.
The NAICS codes for Cyprotex are [541, 54, 54199, 5419].
The SIC codes for Cyprotex are [873, 591, 59, 87].
Top Cyprotex Employees
-
Paul Walker
VP, Head of Toxicology and Innovation Efficiency at Cyprotex
Nether Alderley, GB2 -
Stephen Madden
SVP Head Global Operations Cyprotex at Cyprotex
Macclesfield, GB1 -
55+
-
Alexander Kelly
Director of Business Development at Cyprotex
England, United Kingdom1 -
Simon Thomas
Head of Modelling and Simulation at Cyprotex
Macclesfield, GB11 -
Simon Wood
Head of Analytical Sciences at Cyprotex
United Kingdom1 -
Brian Miller
Operations Manager at Cyprotex
Stockport District, GB12 -
Tom Kaczka
Director of Business Development at Cyprotex
Denver, CO, US45+
Related Companies
